Category Archives: Guest Blog

Germany Post AMNOG

While emerging markets continue to represent a new channel of demand for pharmaceutical products, manufacturers have quickly realized that significant attention must still be given to more established markets, such as Germany. It’s no longer sufficient to expect that regulatory data from prospective randomized clinical studies alone will be enough to convince payers to provide […]
Also posted in Europe, pricing | Tagged , , , , | Leave a comment

Meeting Patient-Centered Expectations in Europe

By Peter O’Donnell, Applied Clinical Trials. The growing insistence on making healthcare more patient-centered — Europe is currently awash with declarations of intent along those lines — is generating a new level of interest in helping patients (or even citizens) to meet the expectations that the new orthodoxy is creating. After all, there is little logic […]
Also posted in Europe, patient education, Regulatory | Tagged , | Leave a comment

We Need to Rock the Boat to Make Research Soar

By Wayne Kubick, Applied Clinical Trials. We hear it all the time these days: research processes have to undergo transformative changes in order for research organizations to thrive—or even survive. Controlled clinical trials take too long and cost too much. Regulatory review is blocking innovation. Research data must be shared transparently, drug manufacturers need to […]
Also posted in Op-Ed, R&D, Strategy | Tagged , | Leave a comment

So Who’s in Charge of Medicines in Brussels?

So now we know who is to do what on health issues in the new European Commission. Or do we? The furor that the new boss of the commission, Jean-Claude Juncker, unleashed with the plans for his new team, weeks before it took office, is still reverberating around Brussels. Peter O’ Donnell reports on the […]
Also posted in Europe, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

The Pharma Leadership Challenge: Thawing the “Frozen” Middle Managers

The challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity. J. Michael Pearson, CEO of Valeant, the Canadian based speciality drugmaker, recently said that “the […]
Also posted in leadership, Strategy | Tagged , , | 1 Comment
  • Categories

  • Meta